Banque Pictet & Cie Sa Alnylam Pharmaceuticals, Inc. Transaction History

Banque Pictet & Cie Sa

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$146.51 - $198.2 $1.49 Million - $2.02 Million	10,176 Added 44.57%	33,005 $4.93 Million
Q4 2023 Feb 09, 2024	SELL	$151.41 - $196.57 $392,908 - $510,099	-2,595 Reduced 10.21%	22,829 $4.37 Million
Q3 2023 Nov 02, 2023	SELL	$170.77 - $211.65 $197,068 - $244,244	-1,154 Reduced 4.34%	25,424 $4.5 Million
Q2 2023 Aug 04, 2023	BUY	$185.01 - $212.05 $3.97 Million - $4.55 Million	21,471 Added 420.42%	26,578 $5.05 Million
Q1 2023 May 01, 2023	SELL	$182.66 - $235.53 $423,040 - $545,487	-2,316 Reduced 31.2%	5,107 $1.02 Million
Q4 2022 Feb 06, 2023	SELL	$185.53 - $241.31 $910,952 - $1.18 Million	-4,910 Reduced 39.81%	7,423 $0
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $691,453 - $1.16 Million	4,991 Added 67.98%	12,333 $2.47 Billion
Q2 2022 Aug 08, 2022	SELL	$120.42 - $169.29 $533,701 - $750,293	-4,432 Reduced 37.64%	7,342 $1.07 Million
Q1 2022 May 04, 2022	SELL	$127.18 - $173.91 $598,636 - $818,594	-4,707 Reduced 28.56%	11,774 $1.92 Million
Q4 2021 Feb 02, 2022	BUY	$159.56 - $209.29 $2.63 Million - $3.45 Million	16,481 New	16,481 $2.8 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.